US10385313B2ActiveUtilityA1

Human IPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings

83
Assignee: US HEALTHPriority: Oct 1, 2013Filed: Oct 1, 2014Granted: Aug 20, 2019
Est. expiryOct 1, 2033(~7.2 yrs left)· nominal 20-yr term from priority
C12N 5/0696C12N 2501/26C12N 5/0018C12N 2500/44C12N 2500/30C12N 2506/45C12N 2501/115C12N 5/0647C12N 5/0661C12N 2506/03C12N 2501/155C12N 2500/05C12N 2501/165C12N 2500/90C12N 5/0662C12N 2500/42C12N 5/0607C12N 2500/36
83
PatentIndex Score
3
Cited by
14
References
10
Claims

Abstract

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A cell culture medium consisting essentially of:
 Iscove's modified Dulbecco's medium (IMDM), 
 Ham's F-12 Nutrient Mix, with L-alanyl-L-glutamine additive, 
 Albumin, 
 a-monothioglycerol, 
 protein-free hybridoma mixture II, 
 L-ascorbic acid 2-phosphate, 
 L-alanyl-L-glutamine, 
 Antibiotic, 
 insulin-transferrin-selenium-ethanolamine supplement, 
 bone morphogenic protein 4, 
 vascular endothelial growth factor, and 
 basic fibroblast growth factor. 
 
     
     
       2. The cell culture medium of  claim 1 , further comprising cholesterol lipids. 
     
     
       3. The cell culture medium of  claim 1 , wherein the antibiotic is selected form the group consisting of penicillin, streptomycin and a mixture of penicillin and streptomycin. 
     
     
       4. The cell culture medium of  claim 1 , wherein the concentration of albumin, is about 5 mg/ml. 
     
     
       5. The cell culture medium of  claim 1 , wherein the concentration of monothioglycerol is from about 350 to about 450 μM. 
     
     
       6. The cell culture medium of  claim 1 , wherein the concentration of L-ascorbic acid 2-phosphate is about 50 μg/ml. 
     
     
       7. The cell culture medium of  claim 1 , wherein the concentration of L-alanyl-L-glutamine is about 1 mM to about 2 mM. 
     
     
       8. The cell culture medium of  claim 1 , wherein the concentration of bone morphogenic protein 4 is about 10 ng/ml. 
     
     
       9. The cell culture medium of  claim 1 , wherein the concentration of vascular endothelial growth factor is about 10 ng/ml. 
     
     
       10. The cell culture medium of  claim 1 , wherein the concentration of basic fibroblast growth factor is about 10 ng/ml.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.